Skip to main content
SpringerLink
Log in

Fingolimod: a guide to its use in multiple sclerosis in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Fingolimod, a novel sphingosine 1-phosphate receptor agonist, is indicated for the treatment of patients with relapsing- remitting multiple sclerosis. In clinical trials, oral fingolimod was more effective than placebo and intramuscular interferon β-1a at reducing annualized relapse rates and the burden and activity of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Scott LJ. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 2011; 25 (8): 673–98

    Article  PubMed  CAS  Google Scholar 

  2. Gilenya: summary of product characteristics. London: European Medicines Agency, 2012 Jul 6

  3. Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 387–401

    Article  PubMed  CAS  Google Scholar 

  4. Haas J, Hartung HP, Von Rosenstiel P, et al. Effect of fingolimod on severe multiple sclerosis relapses, healthcare utilization and recovery: results from two phase 3 studies, TRANSFORMS and FREEDOMS [abstract plus poster. no P06.049]. 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9–16; Honolulu (HI)

  5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362 (5): 402–15

    Article  PubMed  CAS  Google Scholar 

  6. Calabresi PA, Radue E-W, Goodin D, et al. Efficacy and safety of fingolimod in patients with relapsing remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II study) [poster no. E-002]. 64rd Annual Meeting of the American Academy of Neurology; 2012 Apr 21–28; New Orleans (LA)

  7. Cohen J, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon β-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities results from a phase III study (TRANSFORMS) [abstract no. P06.137]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10–17; Toronto (ON)

  8. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10 (6): 520–9

    Article  PubMed  CAS  Google Scholar 

  9. Izquierdo G, O’Connor P, Montalban X, et al. Long-term fingolimod (FTY720) in relapsing MS: 5 years results from an extension of a phase II, multicenter study show a sustained low level of disease activity [abstract plus poster no. PD6.004]. 63rd Annual Meeting of the American Academy of Neurology; 2011 Apr 9–16; Honolulu (HI)

Download references

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Lesley J. Scott & Katherine A. Lyseng-Williamson

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Lyseng-Williamson, K.A. Fingolimod: a guide to its use in multiple sclerosis in the EU. Drugs Ther Perspect 28, 6–11 (2012). https://doi.org/10.1007/BF03262126

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262126

Keywords

Search

Navigation